サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：発作性夜間ヘモグロビン尿症の世界市場－成長、将来展望、競合分析（2022年～2030年）
市場調査レポート
商品コード
1149071

発作性夜間ヘモグロビン尿症の世界市場－成長、将来展望、競合分析（2022年～2030年）

Paroxysmal Nocturnal Hemoglobinuria Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 116 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
発作性夜間ヘモグロビン尿症の世界市場－成長、将来展望、競合分析（2022年～2030年）
出版日: 2022年08月09日
発行: Acute Market Reports
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の発作性夜間ヘモグロビン尿症の市場規模は、2018年の23億4,140万米ドルから、2027年には62億300万米ドルに達し、2019年から2027年までのCAGRは11.7%と予測されています。安価な償還制度、発作性夜間ヘモグロビン尿症に関する公衆衛生意識の高まり、発作性夜間ヘモグロビン尿症に関連した安価な治療を提供するための医療インフラの発展は、発作性夜間ヘモグロビン尿症市場の成長を促進しています。

当レポートでは、世界の発作性夜間ヘモグロビン尿症市場について調査分析し、ビジネス展望、市場力学、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • レポートの説明
    • レポートの目的
    • 対象者
    • 主な製品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ－2次調査
    • フェーズⅡ－1次調査
    • フェーズⅢ－専門家による審査
    • 仮定
    • 採用されたアプローチ

第2章 エグゼクティブサマリー

  • 市場スナップショット：世界の発作性夜間ヘモグロビン尿市場
  • 世界の発作性夜間ヘモグロビン尿症市場（100万米ドル）（2021年）：治療別
  • 世界の発作性夜間ヘモグロビン尿症市場（100万米ドル）：地域別
  • COVID-19の影響
  • 魅力的な投資提案（2021年）：地域別
  • 競合分析
    • 主要な発作性夜間ヘモグロビン尿症市場ベンダーの市場ポジショニング
    • 発作性夜間ヘモグロビン尿症市場のベンダーが採用する戦略
    • 主要な業界戦略

第3章 発作性夜間ヘモグロビン尿症市場：ビジネス展望と市場力学

  • イントロダクション
  • 世界の発作性夜間ヘモグロビン尿症市場金額（100万米ドル）（2020年～2030年）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
    • サプライヤーの力
    • バイヤーの力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競争企業間の敵対関係
  • PESTEL分析
    • 政治的
    • 経済的
    • 技術的
    • 法的
    • 社会的

第4章 発作性夜間ヘモグロビン尿症市場、米ドル（100万）（2020年～2030年）：治療別

  • 市場概要
  • 成長と収益分析：2021年と2030年の比較
  • 市場セグメンテーション
    • 輸血
    • 投薬
    • 幹細胞移植

第5章 北米の発作性夜間ヘモグロビン尿症市場、米ドル（100万）（2020年～2030年）

第6章 英国および欧州連合の発作性夜間ヘモグロビン尿症市場、米ドル（100万）（2020年～2030年）

第7章 アジア太平洋の発作性夜間ヘモグロビン尿症市場、米ドル（100万）（2020年～2030年）

第8章 ラテンアメリカの発作性夜間ヘモグロビン尿症市場、米ドル（100万）（2020年～2030年）

第9章 中東およびアフリカの発作性夜間ヘモグロビン尿症市場、米ドル（100万）（2020年～2030年）

第10章 企業プロファイル

  • Amgen, Inc.
  • Achillion Pharmaceuticals
  • Alexion Pharmaceutcials, Inc.
  • Akari Therapeutics
  • Apellis Pharmaceutcials, Inc.
  • CinnaGen
  • F.Hoffman-La Roche Ltd.
  • Novartis AG
  • Ra Pharmaceuticals
  • Regeneron Pharmaceuticals
図表

List of Tables

  • TABLE 1 Global Paroxysmal Nocturnal Hemoglobinuria Market By Treatment, 2020-2030, USD (Million)
  • TABLE 2 North America Paroxysmal Nocturnal Hemoglobinuria Market By Treatment, 2020-2030, USD (Million)
  • TABLE 3 UK and European Union Paroxysmal Nocturnal Hemoglobinuria Market By Treatment, 2020-2030, USD (Million)
  • TABLE 4 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market By Treatment, 2020-2030, USD (Million)
  • TABLE 5 Latin America Paroxysmal Nocturnal Hemoglobinuria Market By Treatment, 2020-2030, USD (Million)
  • TABLE 6 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Market By Treatment, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Paroxysmal Nocturnal Hemoglobinuria Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Paroxysmal Nocturnal Hemoglobinuria Market: Quality Assurance
  • FIG. 5 Global Paroxysmal Nocturnal Hemoglobinuria Market, By Treatment, 2021
  • FIG. 6 Global Paroxysmal Nocturnal Hemoglobinuria Market, By Geography, 2021
  • FIG. 7 Global Paroxysmal Nocturnal Hemoglobinuria Market, By Treatment, 2021 Vs 2030, %
  • FIG. 8 U.S. Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 9 Canada Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 10 Rest of North America Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 11 UK Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 12 Germany Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 13 Spain Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 14 Italy Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 15 France Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 16 Rest of Europe Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 17 China Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 18 Japan Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 19 India Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 20 Australia Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 21 South Korea Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 22 Rest of Asia Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 23 Brazil Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 24 Mexico Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Latin America Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 26 GCC Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 27 Africa Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Market (US$ Million), 2020 - 2030
目次
Product Code: 138741-08-22

Industry Outlook

The paroxysmal nocturnal hemoglobinuria (PNH) is currently valued at US$ 2,341.4 Mn in 2018 and is set to reach US$ 6,203.0 Mn by 2027 projecting stunning growth at a compounded annual growth rate (CAGR) of 11.7% during the forecast period from 2019 to 2027. PNH is a rare disease wherein red blood cells are reported to burst prematurely. It has a global incidence rate of 1.3 cases per million people. The high treatment cost and mortality rate associated with stem cell transplant procedures has increased the popularity of monoclonal antibodies as the most effective treatment molecule for the treatment of PNH. Presently, 16 drug molecules are being investigated under different stages of clinical trial studies which suggests strong drug pipeline during the forecast period.

"Excellent drug safety and efficacy reported during clinical trial studies and strong product pipeline during the forecast period increase the popularity of monoclonal antibody as first line therapy for PNH"

According to the research findings brought forward by the International Bone Marrow Transplant Registry, hematopoietic stem cell transplantation employing allogeneic donors is the only curative option for patients suffering with paroxysmal nocturnal hemoglobinuria (PNH). However, this treatment module is associated with high mortality rate of 40 to 50%. Eculizumab (Soliris) developed by Alexion Pharmaceuticals, Inc., since its approval in 2007, has revolutionized the treatment regimen for PNH. It is the only licensed drug approved by the USFDA and EMA for the treatment of hemolysis associated with paroxysmal nocturnal hemoglobinuria (PNH). It is basically an anti complement monoclonal antibody which specifically targets the C5 human complement protein and inactivates it thereby increasing the survival rate of PNH patients. Excellent drug safety and efficacy reported in clinical studies and strong product pipeline during the forecast period will increase the popularity of monoclonal antibody as the first line therapy for PNH.

"Presence of major players and affordable reimbursement scenario together drive the market growth in North America"

North America presently represents 35% market share and is spearheading the regional segment paroxysmal nocturnal hemoglobinuria (PNH) market. As per the research citing brought forward by National Institute of Health (NIH), approximately 5,000 people suffer with the disease in the United States. Affordable reimbursement scenario and presence of major players such as Amgen, Inc., Alexion Pharmaceuticals, Roche, Regeneron Pharmaceuticals etc. together drive the market growth in North America region. Europe holds 28% market growth and trails behind North America primarily due to high prevalence rate. According to the statistics provided by National Organization for Rare Disorders (NORD), the prevalence rate of PNH is 15.9 per million people in Europe. European Medical Agency has classified PNH as an orphan disease and has provided fast track designation and orphan drug status for novel drugs developed for its treatment. Asia Pacific accounts for 14.5% market growth owing to the rising public health awareness related to PNH and developing healthcare infrastructure to provide affordable treatment pertaining to PNH.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Paroxysmal Nocturnal Hemoglobinuria market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Paroxysmal Nocturnal Hemoglobinuria market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Treatment

Blood Transfusion

Medication

Stem Cell Transplant

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Paroxysmal Nocturnal Hemoglobinuria market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Paroxysmal Nocturnal Hemoglobinuria market?

Which is the largest regional market for Paroxysmal Nocturnal Hemoglobinuria market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Paroxysmal Nocturnal Hemoglobinuria market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Paroxysmal Nocturnal Hemoglobinuria market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Paroxysmal Nocturnal Hemoglobinuria Market
  • 2.2. Global Paroxysmal Nocturnal Hemoglobinuria Market, By Treatment, 2021 (US$ Million)
  • 2.3. Global Paroxysmal Nocturnal Hemoglobinuria Market, By Geography, 2021 (US$ Million)
  • 2.4. Impact of Covid 19
  • 2.5. Attractive Investment Proposition by Geography, 2021
  • 2.6. Competitive Analysis
    • 2.6.1. Market Positioning of Key Paroxysmal Nocturnal Hemoglobinuria Market Vendors
    • 2.6.2. Strategies Adopted by Paroxysmal Nocturnal Hemoglobinuria Market Vendors
    • 2.6.3. Key Industry Strategies

3. Paroxysmal Nocturnal Hemoglobinuria Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Paroxysmal Nocturnal Hemoglobinuria Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Blood Transfusion
    • 4.3.2. Medication
    • 4.3.3. Stem Cell Transplant

5. North America Paroxysmal Nocturnal Hemoglobinuria Market, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2020-2030, USD (Million)
  • 5.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2020-2030, USD (Million)
    • 5.3.1.North America
      • 5.3.1.1. U.S.
      • 5.3.1.2. Canada
      • 5.3.1.3. Rest of North America

6. UK and European Union Paroxysmal Nocturnal Hemoglobinuria Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2020-2030, USD (Million)
  • 6.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.UK and European Union
      • 6.3.1.1. UK
      • 6.3.1.2. Germany
      • 6.3.1.3. Spain
      • 6.3.1.4. Italy
      • 6.3.1.5. France
      • 6.3.1.6. Rest of Europe

7. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2020-2030, USD (Million)
  • 7.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.Asia Pacific
      • 7.3.1.1. China
      • 7.3.1.2. Japan
      • 7.3.1.3. India
      • 7.3.1.4. Australia
      • 7.3.1.5. South Korea
      • 7.3.1.6. Rest of Asia Pacific

8. Latin America Paroxysmal Nocturnal Hemoglobinuria Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2020-2030, USD (Million)
  • 8.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Latin America
      • 8.3.1.1. Brazil
      • 8.3.1.2. Mexico
      • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Paroxysmal Nocturnal Hemoglobinuria Market: By Treatment, 2020-2030, USD (Million)
  • 9.3.Paroxysmal Nocturnal Hemoglobinuria Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Middle East and Africa
      • 9.3.1.1. GCC
      • 9.3.1.2. Africa
      • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

  • 10.1. Amgen, Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Initiatives
  • 10.2. Achillion Pharmaceuticals
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Initiatives
  • 10.3. Alexion Pharmaceutcials, Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Initiatives
  • 10.4. Akari Therapeutics
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Initiatives
  • 10.5. Apellis Pharmaceutcials, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Initiatives
  • 10.6. CinnaGen
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Initiatives
  • 10.7. F.Hoffman-La Roche Ltd.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Initiatives
  • 10.8. Novartis AG
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Initiatives
  • 10.9. Ra Pharmaceuticals
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Initiatives
  • 10.10. Regeneron Pharmaceuticals
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Initiatives